EPO plus radiotherapy does not improve local-regional control in anemic patients with head and neck cancer
the ONA take:
According to a long-term analysis of a study originally published in 2007, researchers have found that the combination of erythropoietin and radiation therapy did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiotherapy or chemoradiotherapy.
The 2007 Radiation Therapy Oncology Group (RTOG) 9903 study was an open-label, randomized, phase III trial that evaluated whether the addition of erythropoietin to radiotherapy would improve disease control in anemia patients with head and neck squamous cell carcinoma.
For this long-term analysis, results showed that the local-regional failure rate was 39.4% for patients who received radiotherapy or chemoradiotherapy without erythropoietin compared with 46.2% for patients who received erythropoietin at 5-year follow-up (HR = 1.40). Researchers found no statistically significant differences in 5-year progression-free survival, overall survival, or 5-year distant metastases rate between the two groups.
The findings suggest that erythropoietin should not be utilized in anemic patients with head and neck squamous cell carcinoma.
Combination erythropoietin and radiation therapy did not improve control for anemic patients with head and neck squamous cell carcinoma.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|